Articles On Medlab Clinical (ASX:MDC)

Title Source Codes Date
Weed Week: Australian medical cannabis prescriptions are soaring

The number of medical cannabis prescriptions issued under Australia’s special access scheme just keeps on growing. There were a record 9,959 SAS Category B marijuana prescriptions issued in March, two and a half times the number from a year...

Stockhead MDC 2 years ago
Imugene gains 10pc on cancer vaccine progress; 3 other biotechs getting patents

Imugene (ASX:IMU) shares have hit an all-time high after the Sydney biotech company announced its cancer vaccine was continuing to show early promise in a small clinical trial. A cohort review committee has allowed the Phase 1 trial to move...

Stockhead MDC 2 years ago
Why is the Medlab (ASX:MDC) share price surging 8% today?

The Medlab Clinical Ltd (ASX: MDC) share price is rising today after the European Patent Office announced its intention to grant the Australian company a patent for its Nanocelle technology. The Medlab share price is up 8.33% today to 26 c...

Motley Fool MDC 2 years ago
Medlab Clinical to be granted European patent for NanoCelle drug delivery platform

Australian biotech Medlab Clinical (ASX: MDC) has announced it has received notice from the European Patent Office of its intention to grant a patent covering the use of the company’s NanoCelle drug delivery platform. The patent, filed in 2...

SmallCaps MDC 2 years ago
Market highlights and 5 ASX small caps to watch on Wednesday

Wall Street slides, as IMF raises global growth forecast All major US indices slid on Tuesday, but stayed near record highs gained the previous day. Dow Jones closed 0.29% lower, S&P500 dropped 0.1%, while tech heavy NASDAQ slid 0.05%....

Stockhead MDC 2 years ago
Weed Week: Oz cannabis revenue expected to double in 2021 as patients soar

Australia’s medical marijuana industry is showing strong growth, according to an industry-leading biannual report. The Freshleaf Analytics report, released this morning, says that patient numbers have grown 15-fold over the past two and a h...

Stockhead MDC 2 years ago
ScoPo’s powerplays: His Mach7 pick paid off – will Impedimed rise as well?

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week “Another s...

Stockhead MDC 3 years ago
Novartis oncology leader joins board of local biotech

The managing director of Novartis Oncology for Australia and New Zealand, Cheryl Maley, has been appointed to the board of Australian biotechnology company Medlab (ASX:MDC).

BiotechDispatch MDC 3 years ago
Medlab Clinical tops up cash reserves, builds board capabilities with new appointment

Medlab Clinical (ASX: MDC) has topped up its cash reserves with a $15 million placement, while boosting its board expertise with the appointment of “leading” pharmaceutical executive Cheryl Maley. The company announced on Friday it had rais...

SmallCaps MDC 3 years ago
Last Orders: The ASX saw the best IPO of 2021 so far today; but falls 0.73 per cent

The ASX saw the best IPO debut of the year to date in manganese explorer Firebird Metals (ASX:FRB), which rose 198 per cent on debut. This beat the previous 2021 record held by WA telco Pentanet (ASX:5GG), which finished its first day in la...

Stockhead MDC 3 years ago
Check Up: Oneview leads healthcare sector after ‘investor awareness’ pact

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Stockhead MDC 3 years ago
Weed Week: US pot legalisation picks up steam, and the Big Apple could be next

Pot legalisation is creeping across the US state by state, and a major market could be about to join their ranks. Reports out of New York indicate that lawmakers in the Empire State are close to signing a new bill legalising recreational ca...

Stockhead MDC 3 years ago
Why did the market close in red today?

Source: Joyseulay, Shutterstock After a tepid trading session in Wall Street yesterday, the Australian market had a volatile session today. The benchmark index ASX 200 closed at 6785 points with a drop of 41.80 points, a marginal decline o...

Kalkine Media MDC 3 years ago
Last Orders: Tech blooms, but materials & energy drags the ASX down

The ASX finished in the red today dragged down by resources and energy. Materials and Energy stocks lost over 1 per cent each while Tech was the best sector gaining 0.70 per cent. Large caps fared worse than small caps with the ASX 200 losi...

Stockhead MDC 3 years ago
Market continues to remain volatile on Wednesday

Source:Eviart, Shutterstock In the initial trading on Wednesday, the market followed yesterday's pattern and continued with the volatile trading session. After some early gains, it fell steeply and continues to lose points. Most of the...

Kalkine Media MDC 3 years ago
Medlab Clinical hunts $15m cash injection

Medical research and development outfit Medlab Clinical is on the hunt for an equity injection to help fund clinical trails for its chronic disease-treating therapies. 

AFR MDC 3 years ago
Medlab Clinical Share Price Down on Latest Results (ASX:MDC)

The share price of Medlab Clinical Ltd [ASX:MDC] is down more than 2%, trading at 33.5 cents. After an impressive run-up, the MDC share price is now starting to move closer to its January heights where it went as high as 42 cents... The po...

MoneyMorning MDC 3 years ago
Medlab Clinical heads into H2 2021 with strong momentum following ‘very pleasing’ H1

Biotech Medlab Clinical (ASX: MDC) has ended the H1 of the 2021 financial year with $6.8 million cash in the bank with increasing early revenue from Special Access Scheme (SAS) sales of its NanaBis and NanoCBD products along with ongoing nu...

SmallCaps MDC 3 years ago
ASX 200 trades lower towards closing; what’s weighing on stocks?

Summary The ASX 200 was trading in red towards the end of the session, down 80 points to 6,884.40 on Thursday. Most of the sectors were trading in the red. Health Care led the gains in the ASX 200 index, followed by Banks, Consumer Dis...

Kalkine Media MDC 3 years ago
Medlab (ASX:MDC) Join hands with Australia’s largest OTC supplier for NanoCBD™

Summary Medlab Clinical has entered in an exclusive non-binding agreement with Australia’s largest generic pharmaceutical and OTC medicines company. This is the first partnership between a pharma and a biotech company investigating med...

Kalkine Media MDC 3 years ago
Here’s why the Medlab (ASX:MDC) share price is rising today

The Medlab Clinical Ltd (ASX: MDC) share price is on the rise in mid-afternoon trade. This comes after the company announced an agreement with Australia’s largest generic and over the counter pharmaceutical company, Arrotex. Consequently,...

Motley Fool MDC 3 years ago
Medlab Clinical partners with Arrotex to accelerate NanoCBD availability in Australian pharmacies

Medlab Clinical (ASX: MDC) has collared a heads of agreement with Australia’s largest generic over-the-counter (OTC) supplier Arrotex to fast-track availability of its proprietary cannabinoid formulation NanoCBD throughout Australian pharma...

SmallCaps MDC 3 years ago
Medlab Clinical’s probiotic NRGBiotic found to assist in reducing depression symptoms

Preliminary analysis of a phase IIa trial using Medlab Clinical’s (ASX: MDC) probiotic NRGBiotic to help treat major depression has revealed a “significant” reduction in depression. The trial involved administering NRGBiotic to patients dia...

SmallCaps MDC 3 years ago
Jazz Pharmaceuticals woos GW with high-premium US$7.2b offer amid maturing medicinal cannabis sector

ASX-listed cannabinoid stocks are poised for a resurgence after global biopharmaceutical company Jazz Pharmaceuticals lobbed a US$7.2 billion (A$9.4 billion) offer for UK-based medicinal cannabis drug developer GW Pharmaceuticals amid a sof...

SmallCaps MDC 3 years ago
Medlab Clinical to confirm NanaBis’ potential as non-opioid pain treatment in phase three trials

Australian biotech Medlab Clinical (ASX: MDC) could be the world’s first drug developer to have a registered cannabis-based medicine that outperforms opioids for cancer-related pain management, should its upcoming phase three trials be succ...

SmallCaps MDC 3 years ago
How did Medlab (ASX:MDC) Perform in the December Quarter?

Summary Medical research and development company Medlab Clinical provided a quarterly update highlighting its business and quarterly cash flow report. Medlab stated that with the IND approval, it would initiate NanaBis™ pivotal Phase I...

Kalkine Media MDC 3 years ago
Small-cap player Medlab’s (ASX:MDC) shares on watch after IND approval

Summary Australian based medical life science company Medlab Clinical has obtained an IND grant for NanaBis™ from the US FDA. With the FDA approval, Medlab can initiate its pivotal Phase 3 clinical trial at US sites. The Company has a...

Kalkine Media MDC 3 years ago
Medlab Clinical collars US FDA IND approval for cancer-pain treatment NanaBis

Medlab Clinical (ASX: MDC) has collared clinical investigational new drug status from the United States Food and Drug Administration for its lead candidate NanaBis, which is designed for treating cancer-related pain. IND status from the FDA...

SmallCaps MDC 3 years ago
Sean Hall from Medlab Clinical (ASX:MDC)

Medlab Clinical CEO Dr Sean Hall speaks at the Switzer Small and Micro Cap Virtual Investor Day 2020.

Switzer MDC 3 years ago
Podcast: Under the microscope – Medlab Clinical (ASX:MDC), Dr. Sean Hall, CEO and MD.

Morgans analyst Iain Wilkie chats to Dr Sean Hall who is the CEO and MD of drug development company Medlab Clinical (ASX:MDC) on some recent news and upcoming catalysts.

Morgans MDC 3 years ago
Mainstreaming Marijuana: Not What You’d Expect

The New Criterion's Tim Boreham ascertains the impact a proposed regulatory change to medical cannabis will have on the market. By Tim Boreham, Editor, The New Criterion A new world beckons for the listed medical cannabis stocks, but libera...

FNArena MDC 3 years ago
Drawbacks of the TGA’s cannabis changes for listed pot stocks

Having been subject to a harsh reality check over the last year or so, the ASX-listed cannabis sector is applauding the local medicine regulator’s endorsement of the weed as an effective therapy that should be more freely available to the a...

SmallCaps MDC 3 years ago
ScoPo’s health powerplays: Pot stocks get a boost

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes for the week It’s been...

Stockhead MDC 3 years ago
Pot stocks look to launch new products following yesterday’s TGA ruling

ASX cannabis stocks are continuing their victory lap following yesterday’s decision by the TGA to re-classify low-dose cannabidiol (CBD) products. The TGA has made an interim decision to down schedule CBD products, including oil and pills,...

Stockhead MDC 3 years ago
Medlab Clinical – ShareCafe Hidden Gems Webinar Presentation

ShareCafeMedlab Clinical – ShareCafe Hidden Gems Webinar Presentation   Presenter – Sean Hall – CEO & MD – Medlab Clinical is a medical research and development facility researching and formulating novel bio-therapeutics (e.g., nutrace...

ShareCafe MDC 3 years ago
FNArena Corporate Results Monitor – 31-08-2020

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((ALG)) - Ardent Leisure ((AMS)) - Atomos ((AFG)) - Australian Finance ((ASG)) - Autosports Group ((BLD)) - Boral ((CWP)) - Cedar Woods Properties ((CGC)) - Costa Group ((...

FNArena MDC 3 years ago
Hidden Gems Webinar Recap – OSL, MDC, CYP, GSS

ShareCafeHidden Gems Webinar Recap – OSL, MDC, CYP, GSS   We continue to unearth small-cap companies as part of our Hidden Gems webinar series. Catch up on the full webinar with presentations from Oncosil Medical (ASX:OSL), Medlab Clinical...

ShareCafe MDC 3 years ago
Money Talks: Here are 3 biotechs chasing the dream

Money Talks is Stockhead’s regular drill down into the sectors and companies that investors have their eye on right now. Today, we hear from Lincoln Liu, associate director, Investment Banking of Rawson Lewis. Australia’s biotech sector is...

Stockhead MDC 3 years ago
Here’s how Australia offers a strong operating environment for cannabis biotech stocks

In the wake of the 2019 cannabis bear market, plenty of ASX-listed pot stocks are still working to validate their business model in the eyes of investors. But as the space matures, investor attention is also turning to companies adjacent to...

Stockhead MDC 3 years ago
Medlab updates on progress of NanaBis observational study

Australian company Medlab Clinical (ASX.MDC) has reported positive data from the ongoing observational study of NanaBis that is in development as a non-opioid alternative for the treatment of cancer-induced bone pain. 

BiotechDispatch MDC 3 years ago
Capital raisings: Investors upped the ante in June, resources took top spot

In June, ASX-listed companies of all sizes continued to raise capital but the small-cap sector was particularly busy. Stocks with market capitalisations of under $100m at the time of the deal raised $274m in the last month. This is triple M...

Stockhead MDC 3 years ago
Medlab Clinical completes first order of new hybrid cannabinoid to UK

The combination of two formulations, Mg Optima Relax and CBD, promote relaxation and reduces stress.

Proactive Investors MDC 3 years ago
Scopo’s health powerplays: Clinical trials are back

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Clinical t...

Stockhead MDC 3 years ago
Scopo’s health powerplays: Clinical trials are back

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Clinical t...

Stockhead MDC 3 years ago
No marijuana is ok for pregnant women, not even for morning sickness

Another study is pointing to a link between low birth weights and cannabis use during pregnancy, removing another pharmaceutical void for medical marijuana to step into. The peer-reviewed study out of the University of Adelaide’s Robinson R...

Stockhead MDC 3 years ago
Closing Bell: Today’s biggest small cap movers on the ASX

A quick wrap of the key winners and losers on Monday, June 15. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. The ASX had a modest start but tumbled in the las...

Stockhead MDC 3 years ago
Medlab Clinical raises $5.4 million in well-supported placement

A share purchase plan is also underway with proceeds from both activities to smooth the path of the company’s NanaBis™ to Phase 3 trials submissions.

Proactive Investors MDC 3 years ago
Medlab Clinical's NanoCBD available in Australia with first SAS scheme patient supplied

The company’s newest cannabinoid formulation treats patients with chemotherapy-induced nausea and vomiting (CINV).

Proactive Investors MDC 3 years ago
Medlab hunts for fresh capital; Morgans on ticket

Listed medical research and development outfit Medlab Clinical was rattling the tin on Thursday morning for $5.4 million in fresh capital. 

AFR MDC 3 years ago
Scopo’s health powerplays: You’re all going to the pot, literally

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week As markets...

Stockhead MDC 3 years ago